Mer

Zylexis

Zylexis

 Zylexis contains inactivated parapox ovis virus (iPPOV). Due to its large molecular weight, parapox ovis virus is considered a “superantigen” that stimulates strong, immediate non-specific immune response

Zylexis initiates secretion of antiviral interferons and interleukins and stimulates innate immune cells1

Expand All
  • • Treatment is recommended during disease episodes or prior to stress-inducing situations.

    • EHV 1 & 4 infections can be easily triggered by common stressors to horses including transportation, competition, breeding and environmental changes.3

    Dosage regimen in horse and cattle

    * During infections,  3 doses should be given of 2 ml (460 interferon units) of the re-constituted product with a 48 hours interval (day 0, day 2 and day 4), administered intramuscularly

     

    * In Prophylaxes, the first injection is administered 3 days prior to the event (day 0), the second injection 1 day prior to the event (day 2), and the third injection 6 days after the event (day 9) 2

     

    Two Zylexis injections BEFORE and one injection AFTER a stressful event or disease challenge

  • Reduce duration and intensity of the clinical symptoms of infected dogs and cats

    Effective concomitant therapy to accelerate the success of treatment

    Dosage regimen in dog and cat

    In Treatment

    3 doses should be given of 1 ml (230 interferon units) of the re-constituted product with a 48 hours interval (day 0, day 2 and day 4),administered subcutaneously

     

    In Prevention (Prophylaxes)

    If the primary infection is expected within 14 days, the first two injections should be administered within 48 hours (day 0 and day 2) and the third injection should be given on the 9th day

     

    Directions and Precautions:

    • Aseptically rehydrate the freeze-dried component with the sterile diluent provided, shake well before administration.
    • Retreatment is recommended during subsequent disease episodes or prior to stress-inducing situations.
    • Store at 2°- 8° C. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this immunomodulator.

  • 1. Fachinger V, et al. Evidence for a parapox ovis virus-associated superantigen. Eur J Immunol 2000; 30: 2962–2971.

    2. Zylexis Summary of Product Characteristics, April 2012

    3. Ziebell KL, et al. The use of Baypamun N in crowding associated infectious respiratory disease: efficacy of Baypamun N (freeze dried product) in 4 –10 month old horses. Zentralbl Veterinarmed B 1997; 44(9): 529– 536